We also investigated the in vivo antitumor effect of AXL inhibition (TP-0903) on p85β-overexpressing or vector control-expressing DOV13 ovarian cancer xenografts (Supplementary Fig. 9a), which reproduced serous histology consistent with its origin and previous report37,38. This evidence concerns the gene PIK3R2 and ovarian carcinoma.